Although most studies were small and did not include longitudinal outcomes, GGT appeared to perform well for both predicting ≥ F2/F3 fibrosis and MALOs in Pi*ZZ carriers [32, 41]. The gene discussed is SERPINA1; the disease is fibrosis.